探讨BRCA1/2突变在早期卵巢癌（eOC）（国际妇产科联合会FIGO 2014年I-II期）中的作用，及其对复发后预后的影响。在这项多中心回顾性研究中，临床和生存数据来自根据 BRCA 状态对就诊和复发时的高级别浆液性 (HGS)-eOC 患者进行比较：BRCA 突变型 (BRCAmut) 与 BRCA 野生型 (BRCAwt)。在 191 名 HGS-eOC 患者中，89 名是 BRCAmut，102 名是 BRCAwt 。根据 BRCA 状态，无进展生存期 (PFS) 没有显着差异。 BRCAmut 患者的总生存期 (OS) 更长。无论 BRCA 状态如何，I 期患者的 PFS 均较 II 期显着改善。在多变量分析中，诊断时的分期是唯一对 PFS 有显着影响的变量。尽管年龄较小和 BRCA 突变显示出轻微影响，但没有任何因素与 OS 显着相关。与 BRCAwt 相比，BRCAmut 人群的复发后生存率 (PRS) 显着改善。在多变量分析中，二次细胞减灭手术是较长 PRS 的最强预测因素，其次是复发时 PARPi 维持治疗。BRCA 状态并不是早期卵巢癌 PFS 的预后因素。然而，我们的数据表明 BRCAm 人群复发后的预后更好。版权所有 © 2024 Elsevier Inc. 保留所有权利。

To investigate the role of BRCA1/2 mutations in early ovarian cancer (eOC) (International Federation of Gynecology and Obstetrics FIGO 2014 stage I-II), and its impact on prognosis after relapse.In this multicenter retrospective study, clinical and survival data from high-grade serous (HGS)-eOC patients at presentation and recurrence were compared according to BRCA status: BRCA-mutated (BRCAmut) vs. BRCA wild-type (BRCAwt).Among 191 HGS-eOC patients, 89 were BRCAmut and 102 BRCAwt. There was no significant difference according to the BRCA status in terms of Progression-Free Survival (PFS). A longer Overall Survival (OS) was found in BRCAmut patients. Stage I patients had significantly improved PFS vs stage II, regardless of BRCA status. At multivariate analysis, stage at diagnosis was the only variable with a significant effect on PFS. No factors were significantly relevant on OS, albeit younger age and BRCA mutation showed a slight impact. Post-Recurrence Survival (PRS) in the BRCAmut population was significantly improved compared with BRCAwt. At multivariate analysis, Secondary Cytoreductive Surgery was the strongest predictor for longer PRS, followed by PARPi maintenance at recurrence.BRCA-status is not a prognostic factor in early ovarian cancer regarding PFS. However, our data suggest a better prognosis after relapse in BRCAm population.Copyright © 2024 Elsevier Inc. All rights reserved.